IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
Rhea-AI Summary
IceCure Medical (NASDAQ: ICCM) announced it will release its financial and operational results for the six months ended June 30, 2026 before the Nasdaq Stock Market opens on Wednesday, August 12, 2026.
Management will review these results and discuss other corporate developments on a conference call and live webcast at 10:00 a.m. EDT the same day. U.S. investors can join by dialing 1-888-407-2553, while Israel and international participants can dial +972-3-918-0696. A live webcast will be available at https://www.veidan-conferencing.com/icecure-investors, and a recording will later be accessible at ir.icecure-medical.com.
Positive
- None.
Negative
- None.
Market reaction after 1H26 earnings report: ICCM +4.47%
Following this news, ICCM has gained 4.47%, reflecting a moderate positive market reaction. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $3.27.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 06 | First-quarter results date | Neutral | -6.6% | Scheduled first-quarter financial and operating results release and conference call |
| Mar 10 | Full-year results date | Neutral | +0.3% | Scheduled 2025 full-year financial and operating results release |
| Nov 12 | Third-quarter results date | Neutral | +2.5% | Scheduled third-quarter 2025 financial and operating results release |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific record was mixed, with two positive reactions and one negative reaction and an average move of -1.28%.
Key Terms
cryoablation medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call & webcast info:
Wednesday, August 12, 2026, at 10:00 am EDT
US: 1-888-407-2553
A live webcast will be available at: https://www.veidan-conferencing.com/icecure-investors
A recording of the webcast will be available at: ir.icecure-medical.com
About IceCure Medical
IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "should," "could," "seek," "intend," "plan," "goal," "estimate," "anticipate" or other comparable terms. For example, the Company is using forward-looking statements when it discusses the timing for announcing its financial and operating results for the six months ended June 30, 2026 and the related conference call. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2025 filed with the SEC on March 17, 2026, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Investor Relations:
Meir Peleg, CFO
investors@icecure-medical.com
+1-888-902-5716
View original content to download multimedia:https://www.prnewswire.com/news-releases/icecure-medical-to-report-first-half-2026-financial-and-operating-results-on-august-12-2026-302843687.html
SOURCE IceCure Medical